Our findings suggested that blocking the PSC-PCC interaction by inhibiting the SDF-1α/CXCR4 signaling pathways may be a promising therapeutic strategy for overcoming chemoresistance in pancreatic cancer. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.